Hemogenyx Pharmaceuticals Plc - HOPHF STOCK NEWS

Hemogenyx Pharmaceuticals has provided an update on its ongoing activities and progress as of June 17, 2024. The company has added a new US medical center to its HEMO-CAR-T clinical trial sites, enhancing its scope and expediting timelines. It is also expanding the HEMO-CAR-T indication to include pediatric AML and ALL. On the Chimeric Bait Receptor (CBR) platform, Hemogenyx is developing multiple CBR constructs for rare cancers and mRNA-based delivery for viral infections. IND-enabling studies for its CDX bispecific antibody are progressing for treating AML and ALL and conditioning in bone marrow transplants. The company is pursuing non-dilutive financing to support these initiatives.

Hemogenyx Pharmaceuticals has announced the posting of its Annual Report and Accounts for the year ending 31 December 2023. The report, along with the Notice of the Annual General Meeting (AGM) and a Form of Proxy, is now available on the company's website. The AGM will take place on 27 June 2024 at 2:00 pm BST at SP Angel Corporate Finance LLP's offices in London. Hemogenyx Pharmaceuticals focuses on developing new medicines and treatments for blood and autoimmune diseases, aiming to expand the curative power of bone marrow transplants.

Shareholders can find more details on the company's investor relations page. The company has its headquarters in London and operates subsidiaries in New York City. The announcement is distributed by RNS, a news service of the London Stock Exchange, and is compliant with regulations established by the Financial Conduct Authority.

Hemogenyx Pharmaceuticals PLC, a biopharmaceutical group focused on blood diseases, announces its final audited results for 2023. Key highlights include the submission of an IND application for HEMO-CAR-T for AML treatment, FDA authorization for Phase I trials, development of CBR antiviral platform, successful fundraising efforts, and a partnership with Prevail InfoWorks Inc. to support clinical trials. The Chairman's statement discusses progress, challenges with FDA standards, fundraising activities, and future plans for HEMO-CAR-T and other pipeline assets.

Hemogenyx Pharmaceuticals plc announces its total issued share capital and voting rights as of March 28, 2024, consisting of 1,341,815,988 ordinary shares. Shareholders can use this figure for notification purposes under the Financial Conduct Authority's rules.

Hemogenyx Pharmaceuticals plc successfully raised US$4.2 million through a Placing of 166,250,000 new ordinary shares at 2 pence per share. The funds will be used for the development of HEMO-CAR-T for the treatment of AML, following the FDA's lifting of the clinical hold on the IND application. The Company aims to progress HEMO-CAR-T to phase 1 clinical trials, with Placing Shares expected to be admitted to trading on the London Stock Exchange Main Market around 6 March 2024.

Hemogenyx Pharmaceuticals plc announces a breakthrough in delivering Chimeric Bait Receptors (CBR) into the brain via programmed microglial cells for treating brain cancers and neurodegenerative diseases. The method involves genetically modified autologous hematopoietic stem cells. This innovation could potentially offer long-term protection and a renewable source of treatment.

Hemogenyx Pharmaceuticals plc announces successful in vivo demonstration of intranasal delivery of Chimeric Bait Receptor for combating airborne viral infections. The proprietary technology aims to program immune cells to eliminate viruses, with efficient delivery and potential cost-effectiveness. AI tools and in-house mRNA synthesis accelerate research efforts.

Hemogenyx Pharmaceuticals plc (LSE:HEMO) has received approval from the U.S. FDA to proceed with Phase I clinical trials for HEMO-CAR-T, a potential treatment for acute myeloid leukemia (AML). The FDA lifted the clinical hold on the Investigational New Drug (IND) application after the Company addressed all issues satisfactorily. CEO Dr. Vladislav Sandler expressed excitement for the opportunity to accelerate clinical development and provide a potentially life-saving treatment for patients.

Hemogenyx Pharmaceuticals plc (LSE:HEMO) has announced the approval and issuance of a U.S. Conditioning Patent for a method of eliminating Hematopoietic Stem Cells/Hematopoietic Progenitors (HSC/HP) in a patient using Bi-Specific Antibodies. The CEO, Dr. Vladislav Sandler, expressed excitement about the decision, emphasizing the significance of this patent protection for CDX, one of the company's key product candidates for the future. This development reinforces the company's position as a leader in the area of conditioning bone marrow transplants.